Stockscreener 앱 받기
81.99
3.26%
-2.76
Protagonist Therapeutics Inc 주식(PTGX)의 최신 뉴스
Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025 - FinancialContent
Earnings Report: Is Protagonist Therapeutics Inc stock good for income investorsQuarterly Investment Review & AI Based Buy and Sell Signals - baoquankhu1.vn
Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026 - The Desert Sun
Aug Macro: Can Protagonist Therapeutics Inc expand into new marketsM&A Rumor & Weekly Momentum Picks - baoquankhu1.vn
Aug Action: Is BIOX a strong growth stockWeekly Trend Report & Verified Stock Trade Ideas - baoquankhu1.vn
Risk On: Should I add GPUS stock to my portfolio2025 EndofYear Setup & Weekly High Potential Stock Alerts - baoquankhu1.vn
Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis - Daytona Beach News-Journal
With Two Partnered Launches Expected In 2026, Protagonist Looks To Next Chapter - Citeline News & Insights
SG Americas Securities LLC Grows Stock Holdings in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Market Fear: Can Protagonist Therapeutics Inc sustain its profitabilityPortfolio Value Summary & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Trading the Move, Not the Narrative: (PTGX) Edition - Stock Traders Daily
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? - 富途牛牛
Day Trade: Can Protagonist Therapeutics Inc expand into new marketsJuly 2025 Sector Moves & Intraday High Probability Setup Alerts - baoquankhu1.vn
Fundamentals Check: Is Protagonist Therapeutics Inc stock a falling knife or bargain buyShare Buyback & Stepwise Trade Signal Implementation - baoquankhu1.vn
Protagonist Therapeutics, Inc Updates on Clinical Developments and Collaborations - TradingView — Track All Markets
Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting - Greenville Online
Is Protagonist Therapeutics Inc. stock overvalued by current metricsWeekly Risk Report & Verified Momentum Watchlists - ulpravda.ru
Is Protagonist Therapeutics Inc. stock a contrarian buy2025 Investor Takeaways & Reliable Entry Point Alerts - Улправда
Protagonist Therapeutics, Inc.Common Stock (NQ: PTGX - FinancialContent
Can Protagonist Therapeutics Inc. stock rebound after recent weaknessWatch List & AI Driven Stock Reports - Улправда
History Review: How Protagonist Therapeutics Inc. stock benefits from strong dollarJuly 2025 Snapshot & Daily Volume Surge Signals - Улправда
Will Protagonist Therapeutics Inc. stock remain a Wall Street favoriteJuly 2025 Chart Watch & Accurate Intraday Trade Tips - Улправда
Is It Too Late To Consider Protagonist Therapeutics (PTGX) After Its 119% One-Year Surge? - Yahoo Finance
Protagonist Therapeutics Advances Pipeline Amid Financial Loss - MSN
Protagonist Therapeutics, Inc. (PTGX) Stock Analysis: Exploring a 14.44% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Protagonist (PTGX) Stock Pre-Market (-6.4%): NDA Submission For Rusfertide Triggers Sell-The-News - Trefis
Protagonist Therapeutics (PTGX) Target Price Raised by Truist Se - GuruFocus
Truist raises Protagonist Therapeutics stock price target to $110 on pivotal year ahead - Investing.com Canada
Stocks Generating Improved Relative Strength: Protagonist Therapeutics - MSN
Citigroup Initiates Coverage of Protagonist Therapeutics (PTGX) with Buy Recommendation - MSN
Protagonist Therapeutics Earnings Notes - Trefis
(PTGX) Volatility Zones as Tactical Triggers - Stock Traders Daily
Moody Aldrich Partners LLC Sells 27,510 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025 - Galesburg Register Mail
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Exchange Traded Concepts LLC Sells 13,839 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
(PTGX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Protagonist Therapeutics, Inc. $PTGX Shares Purchased by Voya Investment Management LLC - MarketBeat
Assenagon Asset Management S.A. Decreases Stock Holdings in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences - Daytona Beach News-Journal
Protagonist Therapeutics Stock Drop Looks Sharp, But How Deep Can It Go? - Trefis
Aug Selloffs: Why Protagonist Therapeutics Inc stock is recommended by analystsJuly 2025 Pullbacks & Smart Allocation Stock Reports - moha.gov.vn
Jefferies Sticks to Their Buy Rating for Protagonist Therapeutics (PTGX) - The Globe and Mail
4.73%
0.92%
자본화:
|
볼륨(24시간):